Publication Name	World Journal of Cardiology
Manuscript ID	102467
Country	China

Received	2024-10-21 06:33
Peer-Review Started	2024-10-21 06:33
To Make the First Decision
Return for Revision	2024-11-18 09:15
Revised	2024-12-02 08:06
Second Decision	2024-12-13 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-13 07:21
Articles in Press	2024-12-13 07:21
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-12-15 14:36
Typeset the Manuscript	2024-12-31 01:02
Publish the Manuscript Online	2025-01-21 06:56

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Letter to the Editor
Article Title	Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression
Manuscript Source	Invited Manuscript
All Author List	Wei Wang and Charlie Cooper
Funding Agency and Grant Number
Corresponding Author	Wei Wang, Chronic Disease and Health Management Research Center, Geriatric Hospital of Nanjing Medical University, No. 30 Luojia Road, Nanjing 210024, Jiangsu Province, China. wwtxdy@163.com
Key Words	Metabolic dysfunction-associated steatotic liver disease; Type 2 diabetes; Cardiac dysfunction; Left ventricular mass; Sex-hormone binding protein; Fibrosis-4 index scores
Core Tip	Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus, both components of metabolic syndrome, are increasingly recognized for their synergistic impact on cardiovascular health. The intertwined relationship between these conditions amplifies the risk of cardiovascular disease, highlighting the need for integrated management strategies to mitigate this dual threat. Through a comprehensive evaluation of Cernea et al’s study on the combination of MASLD and T2DM in promoting cardiac dysfunction, this editorial provides a comprehensive review of the current research on MASLD and cardiovascular disease, a discusssion of the progress made in this field, and the potential directions for future research.
Publish Date	2025-01-21 06:56
Citation	<p>Wang W, Cooper C. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression. <i>World J Cardiol</i> 2025; 17(1): 102467</p>
URL	https://www.wjgnet.com/1949-8462/full/v17/i1/102467.htm
DOI	https://dx.doi.org/10.4330/wjc.v17.i1.102467

Full Article (PDF)	WJC-17-102467-with-cover.pdf
Manuscript File	102467_Auto_Edited_063922.docx
Answering Reviewers	102467-answering-reviewers.pdf
Audio Core Tip	102467-audio.mp3
Conflict-of-Interest Disclosure Form	102467-conflict-of-interest-statement.pdf
Copyright License Agreement	102467-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	102467-non-native-speakers.pdf
Peer-review Report	102467-peer-reviews.pdf
Scientific Misconduct Check	102467-scientific-misconduct-check.png
Scientific Editor Work List	102467-scientific-editor-work-list.pdf
CrossCheck Report	102467-crosscheck-report.pdf